The DOI matches its Crossref record; 269 of the 269 references it cites were found in a registry or an index.
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessAbstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA augment glucosedependent insulin secretion and glucagon suppression, decelerate gastric emptying, curb postmeal glycemic increments, and reduce appetite, energy intake, and body weight (5,6,164).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, due to their glucose-independent stimulation of insulin secretion, they are associated with an increased risk for hypoglycemia.”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, its ef fi cacy and safety are largely dependent on the education and support provided to facilitate self-management (5,6).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A net energy de fi cit that can be maintained is important for weight loss (5,6,22,72 -74).”
The cited source says what the claim attributes to it.
In the citing paper
“A wide range of physical activities, including leisure time activities, can signi fi cantly reduce HbA1c levels (5,22,121,122).”
The cited source says what the claim attributes to it.
In the citing paper
“metformin has traditionally been recommended as fi rst-line glucoselowering therapy for the management of type 2 diabetes.”
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RA augment glucosedependent insulin secretion and glucagon suppression, decelerate gastric emptying, curb postmeal glycemic increments, and reduce appetite, energy intake, and body weight (5,6,164).”
The cited source says what the claim attributes to it.
In the citing paper
“They have intermediate-to-high glycemic ef fi cacy, with lower glycemic ef fi cacy at lower estimated glomerular fi ltration rate (eGFR).”
The cited source says what the claim attributes to it.
In the citing paper
“The SGLT2i are oral medications that reduce plasma glucose by enhancing urinary excretion of glucose.”
The cited source says what the claim attributes to it.
In the citing paper
“Because of its high ef fi cacy in lowering HbA1c, minimal hypoglycemia risk when used as monotherapy, weight neutrality with the potential for modest weight loss, good safety pro fi le, and low cost, metformin has traditionally been recommended as fi rst-line glucoselowering therapy for the management of type 2 diabetes.”
The cited source says what the claim attributes to it.
In the citing paper
“The primary advantage of insulin therapy is that it lowers glucose in a dose-dependent manner and thus can address almost any level of blood glucose.”
The cited source says what the claim attributes to it.
In the citing paper
“Challenges of insulin therapy include weight gain, the need for education and titration for optimal ef fi cacy, risk of hypoglycemia, the need for regular glucose monitoring, and cost.”
The cited source says what the claim attributes to it.
In the citing paper
“Thiazolidinediones (TZDs) are oral medications that increase insulin sensitivity and are of high glucose-lowering ef fi cacy (5,6).”
The cited source says what the claim attributes to it.
In the citing paper
“As per the previous consensus report and update, sulfonylureas are assessed as having high glucoselowering ef fi cacy, but with a lack of durable effect, and the advantages of being inexpensive and accessible (5,6).”
The cited source says what the claim attributes to it.
In the citing paper
“Longer-acting basal insulin analogs have a lower risk of hypoglycemia than earlier generations of basal insulin, although they may cost more.”
In the citing paper
“Current guidelines in the USA and UK stress the importance of structured and individualised education [21, 22] and European Association for the Study of Diabetes/American Diabetes Association guidelines state the importance of shared decision-making [8, 23].”
In the citing paper
“Lack of adherence and persistence with treatment in T2DM acts as a barrier to achieving glycaemic control [6], increases the risk of microvascular and macrovascular complications [7], and increases healthcare costs [5, 8].”
In the citing paper
“Patient–HCP discussions before treatment initiation may help people with T2DM to better understand their options and allow for individualisation of therapy, as recommended by the American Diabetes Association/European Association for the Study of Diabetes guidelines [8, 23].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–269 of 269
Murphy, M. E., Byrne, M., Galvin, R., Boland, F., Fahey, T., & Smith, S. M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015135 · Cited by 94
Rodbard, H. W., Visco, V. E., Andersen, H., Hiort, L. C., & Shu, D. H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70090-1 · Cited by 91
Mannucci, E., Antenore, A., Giorgino, F., & Scavini, M. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817719290 · Cited by 90
Khera, R., Pandey, A., Chandar, A. K., Murad, M. H., Prokop, L. J., Neeland, I. J., Berry, J. D., Camilleri, M., & Singh, S. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.024 · Cited by 90
O'Neil, P. M., Miller‐Kovach, K., Tuerk, P. W., Becker, L. E., Wadden, T. A., Fujioka, K., Hollander, P. L., Kushner, R. F., Garvey, W. T., Rubino, D., et al. (2016) · Obesity · doi:10.1002/oby.21616 · Cited by 88
A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials
Deacon, C. F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13135 · Cited by 88
Prato, S. D., Camisasca, R., Wilson, C., & Fleck, P. R. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12377 · Cited by 87
Min, S. H., Yoon, J., Hahn, S., & Cho, Y. M. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2818 · Cited by 87
Chan, S. P., & Colagiuri, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.002 · Cited by 84
Giugliano, D., Chiodini, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2015) · Endocrine · doi:10.1007/s12020-015-0718-3 · Cited by 83
Pai, L.-W., Li, T.-C., Hwu, Y.-J., Chang, S.-C., Chen, L.-L., & Chang, P.-Y. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.01.011 · Cited by 80
Tang, H., Li, D., Wang, T., Zhai, S., & Song, Y. (2016) · Diabetes Care · doi:10.2337/dc16-0885 · Cited by 79
Furler, J., O’Neal, D., Speight, J., Manski-Nankervis, J.-A., Gorelik, A., Holmes-Truscott, E., Ginnivan, L., Young, D., Best, J., dean, et al. (2017) · BMJ · doi:10.1136/bmj.j783 · Cited by 78
Tang, H., Cui, W., Li, D., Wang, T., Zhang, J., Zhai, S., & Song, Y. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12785 · Cited by 77
Lipska, K. J., Parker, M. M., Moffet, H. H., Huang, E. S., & Karter, A. J. (2018) · JAMA · doi:10.1001/jama.2018.7993 · Cited by 76
Monami, M., Dicembrini, I., Kundisova, L., Zannoni, S., Nreu, B., & Mannucci, E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12287 · Cited by 72
Esposito, K., Chiodini, P., Maiorino, M. I., Bellastella, G., Capuano, A., & Giugliano, D. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005442 · Cited by 70
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases
Mascolo, A., Rafaniello, C., Sportiello, L., Sessa, M., Cimmaruta, D., Rossi, F., & Capuano, A. (2016) · Drug Safety · doi:10.1007/s40264-016-0399-8 · Cited by 69
Zhang, Y., Hong, J., Chi, J., Gu, W., Ning, G., & Wang, W. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2482 · Cited by 68
Russell-Jones, D., Gall, M.-A., Niemeyer, M., Diamant, M., & Del Prato, S. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.06.005 · Cited by 66
Bach, R. G., Brooks, M. M., Lombardero, M., GENUTH, S. M., Donner, T. W., Garber, A. J., Kennedy, L., Monrad, E. S., Pop‐Busui, R., Kelsey, S. F., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000678 · Cited by 65
Lukashevich, V., Prato, S. D., Araga, M., & Kothny, W. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12229 · Cited by 64
Aronson, R., Reznik, Y., Conget, I., Castañeda, J., Runzis, S., Lee, S., Cohen, O., & for the OpT2mise Study Group (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12642 · Cited by 64
A systematic review and meta-analysis of tai chi for treating type 2 diabetes
Lee, M. S., Jun, J. H., Lim, H.-J., & Lim, H.-S. (2015) · Maturitas · doi:10.1016/j.maturitas.2014.09.008 · Cited by 63
Freemantle, N., Chou, E., Frois, C., Zhuo, Y. D., Lehmacher, W., Vlajnic, A., Wang, H., Chung, H., Zhang, Q., Wu, E. Q., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009421 · Cited by 63
Lasalvia, P., Barahona-Correa, J. E., Romero-Alvernia, D. M., Gil-Tamayo, S., Castañeda-Cardona, C., Bayona, J. G., Triana, J. J., Laserna, A. F., Mejía-Torres, M., Restrepo-Jimenez, P., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816633721 · Cited by 63
Optimisation of follow-up after metabolic surgery
Mingrone, G., Bornstein, S. R., & le Roux, C. W. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30434-5 · Cited by 63
Self-citationEfficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
Erpeldinger, S., Rehman, M. B., Berkhout, C., Pigache, C., Zerbib, Y., Regnault, F., Guérin, É., Supper, I., Cornu, C., Kassaï, B., et al. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0120-z · Cited by 60
Wang, Z., Sun, J., Han, R., Fan, D., Dong, X., Luan, Z., Xiang, R., Zhao, M., & Yang, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13047 · Cited by 59
Karagiannis, T., Liakos, A., Bekiari, E., Athanasiadou, E. A., Paschos, P., Vasilakou, D., Mainou, M., Rika, M., Boura, P., Matthews, D. R., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12541 · Cited by 58
Vijayakumar, T., Jayram, J., Cheekireddy, M., Himaja, D., Teja, Y. D., & Narayanasamy, D. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.01.005 · Cited by 58
Improving diabetes outcomes through lifestyle change—a randomized controlled trial
Delahanty, L. M., Dalton, K. M., Porneala, B., Chang, Y., Goldman, V. M., Levy, D., Nathan, D. M., & Wexler, D. J. (2015) · Obesity · doi:10.1002/oby.21172 · Cited by 55
Self-citationTriple therapy in type 2 diabetes; a systematic review and network meta-analysis
Downes, M., Bettington, E. K., Gunton, J. E., & Turkstra, E. (2015) · PeerJ · doi:10.7717/peerj.1461 · Cited by 55
Pharmacological Approaches in the Treatment and Maintenance of Weight Loss
Gaal, L. V., & Dirinck, E. L. (2016) · Diabetes Care · doi:10.2337/dcs15-3016 · Cited by 55
A1C targets should be personalized to maximize benefits while limiting risks
Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0018 · Cited by 54
Kawalec, P., Mikrut, A., & Łopuch, S. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2494 · Cited by 49
Moses, R. G., Kalra, S., Brook, D., Sockler, J., Monyak, J. T., Visvanathan, J., Montanaro, M., & Fisher, S. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12234 · Cited by 49
Wu, S., Chai, S., Yang, J., Cai, T., Xu, Y., Yang, Z., Zhang, Y., Ji, L., Sun, F., & Zhan, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.07.036 · Cited by 49
Mearns, E. S., Saulsberry, W. J., White, C. M., Kohn, C. G., Lemieux, S., Sihabout, A., Salamucha, I., & Coleman, C. I. (2015) · Diabetic Medicine · doi:10.1111/dme.12837 · Cited by 46
Aquatic exercise for adults with type 2 diabetes: a meta-analysis
Rees, J., Johnson, S. T., & Boulé, N. G. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1023-9 · Cited by 46
Rosenstock, J., Fonseca, V. A., Schinzel, S., Dain, M., Mullins, P. R., & Riddle, M. C. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.04.003 · Cited by 44
Owens, D. R., Traylor, L., Mullins, P. R., & Landgraf, W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.022 · Cited by 43
Aggarwal, N., Singla, A., Mathieu, C., Montanya, E., Pfeiffer, A. F. H., JOHNSSON, E. K., Zhao, J., Iqbal, N., & Bailey, C. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13104 · Cited by 43
Self-citationHuber, C. A., & Reich, O. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s115425 · Cited by 42
Anjana, R. M., Kesavadev, J., Neeta, D., Tiwaskar, M., Pradeepa, R., Jebarani, S., Thangamani, S., Sastry, N. G., Brijendra Kumar, S., Ramu, M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0063 · Cited by 42
Foroutan, N., Muratov, S., & Levine, M. (2016) · Clinical and investigative medicine · doi:10.25011/cim.v39i2.26481 · Cited by 41
Aschner, P. J., Sethi, B. K., Peralta, F. G., Landgraf, W., Loizeau, V., Dain, M., Pilorget, V., & Çömlekçi, A. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.04.003 · Cited by 40
Chen, K., Kang, D., Yu, M., Zhang, R., Zhang, Y., Chen, G., & Mu, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13147 · Cited by 40
Wang, C., Mamza, J., & IDRIS, I. R. (2015) · Diabetic Medicine · doi:10.1111/dme.12694 · Cited by 38
Goldman, J. D., Kapitza, C., Pettus, J., & Heise, T. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335192 · Cited by 38
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
Lee, C., Woodward, M., & Colagiuri, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.037 · Cited by 37
Tabesh, M., Magliano, D. J., Koye, D. N., & Shaw, J. E. (2018) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2017.08.018 · Cited by 35
Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol
McGovern, A. P., Tippu, Z., Hinton, W., Munro, N. M., Whyte, M., & de Lusignan, S. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010469 · Cited by 34
Anyanwagu, U., Mamza, J., Gordon, J. P., Donnelly, R., & IDRIS, I. R. (2017) · Diabetic Medicine · doi:10.1111/dme.13518 · Cited by 34
Aroda, V. R., Bailey, T. S., Cariou, B., Kumar, S., Leiter, L., Raskin, P., Zacho, J., Andersen, T. H., & Philis‐Tsimikas, A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12661 · Cited by 33
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Is insulin the most effective injectable antihyperglycaemic therapy?
Buse, J. B., Peters, A., Russell‐Jones, D., Furber, S., Donsmark, M., Han, J., MacConell, L., Maggs, D., & Diamant, M. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12402 · Cited by 32
Self-citationMoses, R. G., Round, E., Shentu, Y., Golm, G. T., O’Neill, E. A., Gantz, I., Engel, S. S., Kaufman, K. D., & Goldstein, B. J. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12351 · Cited by 32
Zaccardi, F., Dhalwani, N. N., Dales, J., Mani, H., Khunti, K., Davies, M. J., & Webb, D. R. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13185 · Cited by 31
Self-citationWysham, C., Lin, J., & Kuritzky, L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1297669 · Cited by 28
Yang, W., Cai, X., Gao, X., Chen, Y., Chen, L., & Ji, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12764 · Cited by 27
Changes in metformin use in chronic kidney disease
Imam, T. H. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx017 · Cited by 25
Hong, A.-R., Lee, J., Ku, E. J., Hwangbo, Y., Kim, K. M., Moon, J. H., Choi, S. H., Jang, H. C., & Lim, S. K. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.019 · Cited by 20
Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., & Schmitt, H. (2017) · Diabetic Medicine · doi:10.1111/dme.13390 · Cited by 16
Manski-Nankervis, J.-A., Furler, J., O’Neal, D., Ginnivan, L., Thuraisingam, S., & Blackberry, I. (2017) · Primary Care Diabetes · doi:10.1016/j.pcd.2017.06.005 · Cited by 15
Esposito, K., Maiorino, M. I., Ciotola, M., Di Palo, C., Scognamiglio, P., Gicchino, M., Petrizzo, M., Saccomanno, F., Beneduce, F., Ceriello, A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00004 · Cited by 13
Khunti, K., Damcı, T., Husemoen, L. L. N., Babu, V., & Liebl, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.11.028 · Cited by 9
Linjawi, S., Lee, B., Tabak, Ö., Lövdahl, S., Werther, S., & Abusnana, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0334-8 · Cited by 8
Barbero (2014) · doi:10.1016/j · Cited by 1
Flagged first, then by citations
Cited by
Sorted by citations
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“Most other glucose-lowering agents, except for sodium/glucose cotransporter-2 (SGLT-2) inhibitors, usually lead to some weight gain (sulfonylureas, insulin, or thiazolidinediones) or are weight neutral (metformin, DPP-4 inhibitors, or a-glucosidase inhibitors) [47].”
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citation
Metadata
- Authors
- Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Duke University (US)
- National Institutes of Health (US)
- Yale University (US)
- Universitair Ziekenhuis Leuven (BE)
- King's College London (GB)
- University of Copenhagen (DK)
- Harvard University (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Davies, Melanie J.
- ORCID
- Venue
- Diabetologia
- Published
- 2018-10-05
- Volume
- 61
- Issue
- 12
- Pages
- 2461-2498
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2895533920
- Cited by
- 1,455
- References
- 269
- Citations by year
- 2026: 22 · 2025: 54 · 2024: 78 · 2023: 127 · 2022: 195 · 2021: 297 · 2020: 420 · 2019: 235 · 2018: 23
- FWCI
- 192.73
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-03-21)
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (acceptedVersion, cc-by)
- Lirias (submittedVersion, other-oa)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Health and Human Services (UL1TR002489)
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Massachusetts General Hospital
- Yale University
- Gilead Sciences
- University of Pennsylvania
- Emory University
- Washington State University
- University of Washington
- Tulane University
- Universitat de Girona
- National University of Ireland
- Intarcia Therapeutics
- MannKind Corporation
- Steno Diabetes Center Copenhagen (SDCC 3.A Complications)
- University of Leicester
- University of Southampton
- University of Oxford
- Newcastle University
- University of Galway
- European Foundation for the Study of Diabetes
- Novo Nordisk
- Universitetet i Oslo
- Università di Pisa
- European Association for the Study of Diabetes
- Servier
- Mitsubishi Tanabe Pharma Corporation
- National Institutes of Health (UL1TR002489)
- Takeda Pharmaceuticals International
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, lifestyle management, diabetes self-management education and support, obesity, weight loss, bariatric surgery, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular disease, chronic kidney disease, heart failure, atherosclerotic cardiovascular disease, antidiabetic drugs
- MeSH terms
- Liraglutide, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Europe, Heart Failure, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, United States, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
